Clinical Study On Hypercoagulabe State Of Elderly Patients With Lung Cancer

Objective:Analyze clinical feature and characteristics of coagulation parameters in elderly patients of lung cancer with hypercoagulability.Aimed to investigate new strategy for prevention and treatment for elderly patients with hypercoagulability.Method:Selected 183 patients of Department of Respiratory Medicine,The First Affiliated Hospital of Zhejiang University School of MedicineFwith lung cancer from October 2011 to December 2014,and the age of the enrolled patients is over 70 years.Collect the results of the patients of clinical stage,coagulation results,histological type,ECOG score and comorbidities.Toinvestigate the clinical and coagulatable characteristics of the enrolled patients by demonstrating a correlation analysis.Results:1.183 cases of lung cancer patients of initial diagnosis were enrolled in this study,and 90 cases at the time diagnosis have been combined with hypercoagulability,the incidence of hypercoagulability was 49.2%.2.The proportion of NSCLC in the enrolled patients was higher than that of SCLC(63.4%vs36.6%,P<0.05).The proportion of NSCLC in the hypercoagulable group was higher than that in the non-hypercoagulable group(P<0.05,respectively),but the proportion of SCLC in the hypercoagulable group was lower than that in the non-hypercoagulable group(P<0.05,respectively).There was no statistical difference in clinical stage in the hypercoagulable group compared to the non-hypercoagulable group,or NSCLC compared to SCLC(P>0.05,respectively).3.The comorbidities of patients with lung cancer include diabetes,hypertension,infection and pleural effusion.The proportion of diabetes,hypertension and pleural effusion was significantly high in the hypercoagulable group than that in non-hypercoagulable group(P<0.05,respectively).4.The value of FIB and DD in the hypercoagulable group was significantly higher than that in the non-hypercoagulable group,but the value of PT sharply decreased in the hypercoagulable group compared to the non-hypercoagulable group(P<0.05,respectively).5.The value of FIB and DD in the patients with age over 75 years was significantly higher than that in the patients with age under 75 years(P<0.05).6.The value of FIB and DD in ?/? stage with NSCLC was significantly higher than that in I/II stage patients,similarly,the value of FIB and DD in extensive stage with SCLC was significantly higher than that in limited stage patients(P<0.05,respectively).7.The value of FIB and DD in the patients with ECOG over 2 was significantly higher than that in the ECOG under 2,but the value of APTT sharply decreased in the ECOG over 2 groups compared to the ECOG under 2 groups(P<0.05,respectively).8.The value of FIB and DD in the patients with comorbidities was significantly higher than that in the patients without comorbidities(P<0.05).Conclusions:1.Female,age over 75 and platelet elevation were independent risk factors for elderly patients with lung cancer with hypercoagulability.2.The proportion of non-small cell lung cancer in hypercoagulable group was higher than that in non-hypercoagulable group,while the proportion of small cell lung cancer in hypercoagulable group was lower than that in non-hypercoagulable group.3.Clinical stage,ECOG score and comorbidities are closely related to blood hypercoagulability in elderly patients with lung cancer.